https://www.globenewswire.com/fr/news-release/2025/12/10/3203120/0/en/Barinthus-Bio-Announces-Update-on-Phase-1-AVALON-Clinical-Trial-of-VTP-1000-for-the-Treatment-of-Celiac-Disease.html
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000...
barinthusbioannouncesupdatephase
https://www.globenewswire.com/fr/news-release/2025/09/30/3158558/0/en/Barinthus-Biotherapeutics-to-Combine-with-Clywedog-Therapeutics-to-Target-Metabolic-and-Autoimmune-Diseases.html
The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being...
barinthus biotherapeuticscombineclywedog
https://www.globenewswire.com/fr/news-release/2025/09/30/3158744/0/en/Barinthus-Biotherapeutics-to-Combine-with-Clywedog-Therapeutics-to-Target-Metabolic-and-Autoimmune-Diseases.html
GERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The combined company, Clywedog Therapeutics, will bring a portfolio that includes...
barinthus biotherapeuticscombineclywedog
https://www.macrotrends.net/stocks/charts/BRNS/barinthus-biotherapeutics/total-share-holder-equity
Barinthus Biotherapeutics share holder equity from 2020 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
barinthus biotherapeuticsshare holderequitybrnsmacrotrends